Why do I need to take ziprasidone with food?

Ziprasidone has poor absorption on an empty stomach — taking it without food results in only about 60% of the expected blood levels. A meal of at least 500 calories (any type) approximately doubles the absorption. This is one of the most important practical aspects of ziprasidone therapy, as inconsistent food intake leads to variable drug levels and potentially inconsistent symptom control.

Does ziprasidone cause weight gain like other antipsychotics?

Ziprasidone causes significantly less weight gain than many other atypical antipsychotics (particularly olanzapine, clozapine, and quetiapine). In the CATIE trial, ziprasidone was associated with modest weight loss on average, while olanzapine caused an average gain of about 2 lbs/month. It also has a more favorable lipid and glucose profile. However, metabolic monitoring is still recommended.

What is QTc prolongation and why does it matter?

The QTc interval measures the time for the heart's ventricles to electrically repolarize. Prolongation increases the risk of a dangerous arrhythmia called torsades de pointes, which can cause fainting or cardiac arrest. Ziprasidone prolongs the QTc by about 20 ms on average — more than most other antipsychotics but less than medications like thioridazine. Your doctor may check periodic ECGs, especially when starting treatment or if risk factors change.

How long do I need to take ziprasidone?

For schizophrenia, long-term (often indefinite) treatment is usually recommended, as stopping antipsychotics significantly increases relapse risk. For bipolar disorder, the duration depends on the treatment context — acute mania episodes may require shorter courses, but many patients benefit from long-term maintenance. Never stop abruptly — always taper under medical guidance.

What to Expect When Starting Ziprasidone

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Ziprasidone (brand name Geodon) is an atypical (second-generation) antipsychotic prescribed for schizophrenia and acute bipolar mania ^[1]. It works primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors, with additional activity at 5-HT1A (partial agonist), 5-HT2C, histamine H1, and alpha-1 adrenergic receptors ^[2]. Ziprasidone is notable among atypical antipsychotics for its relatively low risk of weight gain and metabolic syndrome, but it carries a greater risk of QTc interval prolongation, which requires careful monitoring.

Week-by-week timeline

Day 1-7QTc prolongation is the key safety concern. Avoid combining ziprasidone with other QTc-prolonging medications, and report any palpitations, dizziness, or fainting.

Starting Treatment

For schizophrenia, begin at 20 mg twice daily with food, increasing to 40-80 mg twice daily over the first few days based on response [1]. Food is essential — taking ziprasidone with a meal of at least 500 calories doubles its absorption [2]. Common early side effects include somnolence (14%), nausea (10%), dizziness (8-16%), and restlessness (akathisia, 2-10%). A baseline ECG is often obtained to measure the QTc interval, as ziprasidone can prolong it by approximately 20 ms on average [1].

Week 1-4While ziprasidone is metabolically favorable, it is not metabolically neutral. Periodic metabolic monitoring (fasting glucose, lipids, weight) is still recommended.

Dose Optimization

The dose is titrated to 60-80 mg twice daily based on clinical response for schizophrenia [1]. For bipolar mania, doses of 40-80 mg twice daily are used. Antipsychotic effects typically begin within the first 1-2 weeks for acute symptoms, with continued improvement over 4-6 weeks [2]. Sedation often decreases as the body adjusts. Extrapyramidal symptoms (EPS) — including muscle stiffness, tremor, and restlessness — occur in 5-15% of patients and are dose-related. Ziprasidone causes significantly less weight gain and metabolic disturbance than olanzapine, clozapine, or quetiapine [1].

Month 1-3If significant improvement has not occurred after 6-8 weeks at adequate doses, discuss alternative treatments with your doctor.

Full Therapeutic Effect

By 4-8 weeks at a therapeutic dose, the full antipsychotic effect should be emerging [2]. Positive symptoms (hallucinations, delusions) typically respond first, while negative symptoms (social withdrawal, flat affect) and cognitive symptoms improve more gradually. For bipolar mania, mood stabilization is usually apparent by 3-4 weeks. Side effects have generally stabilized. Prolactin elevation can occur (though less than with risperidone), potentially causing menstrual changes in women or breast tenderness [1].

Month 3-6Continue ziprasidone as prescribed even when feeling well — discontinuing antipsychotics significantly increases relapse risk in schizophrenia and bipolar disorder.

Long-Term Stabilization

Ziprasidone provides sustained symptom control with maintenance dosing. The CATIE trial compared several atypical antipsychotics and found that while ziprasidone was not the most effective for all-cause discontinuation, it had the best metabolic profile among the comparators [3]. Long-term monitoring includes periodic ECGs (especially if risk factors for QTc prolongation change), metabolic panels, and clinical assessment for tardive dyskinesia — a potentially irreversible movement disorder that can develop with any antipsychotic [1].

When to call your doctor

Contact your healthcare provider if you experience:

Fainting, severe dizziness, or palpitations — may indicate QTc prolongation or cardiac arrhythmia. Seek immediate evaluation [1]
Muscle rigidity, high fever, altered consciousness, and autonomic instability — may indicate neuroleptic malignant syndrome (NMS), a rare but life-threatening reaction [1]
Involuntary repetitive movements of the tongue, face, jaw, or limbs — may indicate tardive dyskinesia, which can become permanent [1]
Severe restlessness or inability to sit still (akathisia) interfering with daily function [2]
Signs of metabolic changes: excessive thirst, frequent urination, significant weight gain, or unexplained fatigue [1]
Suicidal thoughts, worsening depression, or significant behavioral changes [1]

Tips for getting started

Always take ziprasidone with food — a meal of at least 500 calories doubles absorption, and inconsistent food intake causes unpredictable drug levels ^[1]. Take it at the same times each day (typically morning and evening with meals). Stay well hydrated and avoid overheating, as antipsychotics can impair thermoregulation ^[2]. Avoid alcohol, which increases sedation and can worsen QTc prolongation. Inform your doctor of all medications, as many drugs interact with ziprasidone through CYP3A4 metabolism or additive QTc effects. Do not stop abruptly — taper under medical supervision to avoid withdrawal symptoms or psychotic relapse.

Frequently asked questions

More about Ziprasidone

Ziprasidone drug guideSide effects, dosage, interactions, and more Aripiprazole vs ZiprasidoneCompare these medications Quetiapine vs ZiprasidoneCompare these medications Ziprasidone & EscitalopramInteraction details

References

[Regulatory] Geodon (ziprasidone) FDA Prescribing Information. Pfizer. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020825s051lbl.pdf Accessed 2025-01-15.
[Regulatory] Ziprasidone. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK448142/ Accessed 2025-01-15.
[Clinical] Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med. 2005;353(12):1209-1223. https://pubmed.ncbi.nlm.nih.gov/16172203/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026